Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply

Abstract:
NANOBIOTIX (Euronext: NANO-ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced the appointment of Thierry Otin as Head of Manufacturing and Supply. The appointment strengthens the Nanobiotix organisation, Mr Otin will be responsible for the manufacturing plans to move the lead product, NBTXR3, from clinical trials into full commercialization as from 2016.

Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply

Paris, France | Posted on April 15th, 2014

Prior to joining Nanobiotix, Mr Otin was the Quality Site Manager (EU Sterile) at Roche and before then, he worked at LFB Biotechnologies as the Head Pharmacist (Pharmaceutical Qualified Person) and Quality Director. Prior to this, he worked in QA/GMP and manufacturing with world class companies including, Schering CISBiointernational, Institut de Formation des Industries de Santé (IFIS), UCB, Delagrange and Rhône-Poulenc (Roger Bellon and Specia). He has a degree in biology and has a doctorate in Pharmacy from the University of Strasbourg.

Laurent Levy, CEO of Nanobiotix said: "Thierry Otin joins us having had over 30 years' experience in the global pharmaceutical industry which includes 12+ years' experience of injectable drug production management and 11+ years in QA senior compliance management. This wealth of expertise will be invaluable to us as we move our lead product to commercialization. We welcome him to the team."

####

About Nanobiotix
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration.
Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The Company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

Issued for and on behalf of Nanobiotix by Instinctif Partners.

For more information, please click here

Contacts:
Sarah Gaubert
Head of Communication
and Public Affairs
+33 (0)1 40 26 07 55


Media Relations
France - NewCap
Annie-Florence Loyer/ Nadège Le Lezec
+33 (0)6 88 20 35 59
/

Financial communication and investors relations
NewCap.
Louis-Victor Delouvrier / Emmanuel Huynh
+33 (0)1 44 71 98 53


Instinctif Partners
Melanie Toyne Sewell / Katherine Lynch / Donia Al Saffar
+44 (0) 207 457 2020

Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Haydale and Goodfellow Announce Major Distribution Agreement for Functionalised Graphene Materials July 21st, 2014

Relaunch of the Nanoscribe Website New design, optimized research, and impressive gallery of applications July 21st, 2014

Dongbu HiTek Unveils Low-Voltage BCDMOS Process for Efficient Power Management in Smart Phones and Tablet Computers July 21st, 2014

Iran to Host 1st Asian Congress on Nanostructures on Kish Island July 21st, 2014

Nanomedicine

SentiMag® Now Available in Australia and New Zealand July 21st, 2014

More than glitter: Scientists explain how gold nanoparticles easily penetrate cells, making them useful for delivering drugs July 21st, 2014

Iranian Scientists Use Nanosensors to Achieve Best Limit for Early Cancer Diagnosis July 19th, 2014

Production of Non-Virus Nanocarriers with Highest Amount of Gene Delivery July 17th, 2014

Announcements

Oxford Instruments Asylum Research Opens an Atomic Force Microscopy Demonstration Lab in Mumbai, India July 21st, 2014

Steam from the sun: New spongelike structure converts solar energy into steam July 21st, 2014

More than glitter: Scientists explain how gold nanoparticles easily penetrate cells, making them useful for delivering drugs July 21st, 2014

Iran to Host 1st Asian Congress on Nanostructures on Kish Island July 21st, 2014

Appointments/Promotions/New hires/Resignations/Deaths

NSS Pays Tribute to Space Pioneer Frederick I. Ordway III July 7th, 2014

Harris & Harris Group Announces Changes to Its Legal Department June 9th, 2014

SEMATECH Appoints Satyavolu Papa Rao to Lead Process Technology May 13th, 2014

Agilent Technologies Names Jay Alexander as Chief Technology Officer of Keysight Technologies May 7th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE